Literature DB >> 26309519

Regulatory T cells and IL-17(+) T helper cells enhanced in patients with chronic hepatitis B virus infection.

Hao Feng1, Jie Yin2, Ya-Ping Han3, Xiao-Ying Zhou3, Su Chen2, Li Yang2, Jin-Rui Yan2, Guo-Xin Zhang3.   

Abstract

Hepatitis B is a worldwide infectious disease caused by hepatitis B virus (HBV), it leaded to millions of deaths every year, HBV mainly through immune response to damage liver cells. The purpose of this study was to judge the value of Regulatory T cells (Treg) and IL-17(+) T helper cells (Th17) in different chronic HBV infection stages. 96 patients with chronic HBV infection were enrolled and selected 33 healthy adults as control. Detected the expression of Treg and Th17 cells in peripheral blood by flow cytometry and assayed liver function simultaneously. Compared to the control group, the expression of Treg (6.80±1.92 vs. 4.42±0.97; P<0.0001) and Th17 (6.15±4.20 vs. 2.66±1.79; P<0.0001) cells were both increased and the ratio of Treg/Th17 was significantly decreased (1.48±0.89 vs. 2.29±1.31; P=0.0001) in patients with HBV infection. Spearman correlation analysis demonstrated that the level of Treg and Th17 cells were associated with liver function. ROC curve analysis found that Treg and Th17 cells were suitable for as a screening test for early detection of the disease. In conclusion, the expression of Treg and Th17 cells were increased in chronic hepatitis B patients and these indicators were independent risk factors to hepatitis.

Entities:  

Keywords:  Th17; Treg; cirrhosis; hepatitis B; hepatocellular carcinoma

Year:  2015        PMID: 26309519      PMCID: PMC4538083     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  30 in total

1.  The Treg/Th17 imbalance in patients with idiopathic dilated cardiomyopathy.

Authors:  J Li; L Wang; S Wang; H Zhu; P Ye; A Xie; B Shen; C Liu; C Guo; Q Fu; K Zhang; J Xia
Journal:  Scand J Immunol       Date:  2010-04       Impact factor: 3.487

2.  Alveolar granulocytic sarcoma of the mandible in a patient with HIV.

Authors:  Nataša Colović; Vladimir Jurišić; Tatjana Terzić; Djordje Jevtovic; Milica Colović
Journal:  Onkologie       Date:  2011-01-17

Review 3.  Pivotal roles of the interleukin-23/T helper 17 cell axis in hepatitis B.

Authors:  Zemin Huang; Jennifer C van Velkinburgh; Bing Ni; Yuzhang Wu
Journal:  Liver Int       Date:  2012-02-19       Impact factor: 5.828

4.  A proinflammatory role for interleukin-22 in the immune response to hepatitis B virus.

Authors:  Ye Zhang; Melissa A Cobleigh; Jian-Qi Lian; Chang-Xing Huang; Carmen J Booth; Xue-Fan Bai; Michael D Robek
Journal:  Gastroenterology       Date:  2011-06-25       Impact factor: 22.682

5.  Involvement of Th17 and Th1 effector responses in patients with Hepatitis B.

Authors:  Yufu Ye; Xiaojun Xie; Jiwei Yu; Lin Zhou; Haiyang Xie; Guoping Jiang; Xiaobo Yu; Wenjin Zhang; Jian Wu; Shusen Zheng
Journal:  J Clin Immunol       Date:  2010-07       Impact factor: 8.317

6.  Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B.

Authors:  Dongping Xu; Junliang Fu; Lei Jin; Hui Zhang; Chunbao Zhou; Zhengsheng Zou; Jing-Min Zhao; Bin Zhang; Ming Shi; Xilai Ding; Zirong Tang; Yang-Xin Fu; Fu-Sheng Wang
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

Review 7.  Development and function of interleukin 17-producing γδ T cells.

Authors:  Thomas Korn; Franziska Petermann
Journal:  Ann N Y Acad Sci       Date:  2012-01-12       Impact factor: 5.691

Review 8.  Immunology of hepatitis B infection.

Authors:  Maria-Christina Jung; Gerd R Pape
Journal:  Lancet Infect Dis       Date:  2002-01       Impact factor: 25.071

9.  Decreased ratio of Treg cells to Th17 cells correlates with HBV DNA suppression in chronic hepatitis B patients undergoing entecavir treatment.

Authors:  Ji-Yuan Zhang; Chun-Hui Song; Feng Shi; Zheng Zhang; Jun-Liang Fu; Fu-Sheng Wang
Journal:  PLoS One       Date:  2010-11-08       Impact factor: 3.240

10.  Antibody-directed complement-mediated cytotoxicity to hepatocytes from patients with chronic hepatitis B.

Authors:  T I Michalak; J Y Lau; B M McFarlane; G J Alexander; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

View more
  7 in total

1.  BATF Interference Blocks Th17 Cell Differentiation and Inflammatory Response in Hepatitis B Virus Transgenic Mice.

Authors:  Long-Yan Chen; Xiao-Peng Fan; Yu-Chen Fan; Jing Zhao; Shuai Gao; Feng Li; Zhao-Xia Qi; Kai Wang
Journal:  Dig Dis Sci       Date:  2018-11-29       Impact factor: 3.199

2.  [Effects of hepatitis B virus on Th17, Treg and Th17/Treg ratio in different alanine aminetransferase stages].

Authors:  P Gao; Y P Luo; J F Li; I Chen; X R Mao
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-18

Review 3.  Role of T Regulatory Cells and Myeloid-Derived Suppressor Cells in COVID-19.

Authors:  Alhasan Alsalman; Mohammad A Al-Mterin; Eyad Elkord
Journal:  J Immunol Res       Date:  2022-04-19       Impact factor: 4.493

Review 4.  Immunity and Fibrogenesis: The Role of Th17/IL-17 Axis in HBV and HCV-induced Chronic Hepatitis and Progression to Cirrhosis.

Authors:  Feliciano Chanana Paquissi
Journal:  Front Immunol       Date:  2017-09-28       Impact factor: 7.561

5.  Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients.

Authors:  Long-Shan Ji; Qiu-Tian Gao; Ruo-Wen Guo; Xin Zhang; Zhen-Hua Zhou; Zhuo Yu; Xiao-Jun Zhu; Ya-Ting Gao; Xue-Hua Sun; Yue-Qiu Gao; Man Li
Journal:  J Immunol Res       Date:  2019-01-13       Impact factor: 4.818

Review 6.  Cytokines and Chemokines in HBV Infection.

Authors:  Shihong Zhong; Tianling Zhang; Libo Tang; Yongyin Li
Journal:  Front Mol Biosci       Date:  2021-12-02

7.  Treg/Th17 Cell Balance in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure at Different Disease Stages.

Authors:  Nian-Hua Tan; Bin Chen; Jie Peng; Shan Du
Journal:  Biomed Res Int       Date:  2021-11-26       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.